View More Recent Stories
-
Moderna (MRNA) +9% as Jefferies says the market is nearing short term 'peak RFK negativity'
-
Jefferies Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Hold
-
Guggenheim Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
-
GSK (GSK) Sues Moderna (MRNA) for US Patent Infringement Over MRNA Technology in Covid-19 Vaccines - Court Filing
-
GSK (GSK) to Settle Zantac Product Liability Cases for up to $2.2B
-
GSK (GSK) halted, news pending
-
GSK (GSK) Presents Positive Data for AREXVY
-
Pfizer (PFE) invalidates two GSK (GSK) RSV vaccine patents in U.K.
-
GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to GBP20 at Jefferies
-
GSK (GSK) Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
-
TD Cowen Reiterates Hold Rating on GlaxoSmithKline (GSK:LN) (GSK)
-
GSK (GSK) announces positive results from phase III trial of Nucala (mepolizumab) in COPD
-
Deutsche Bank Reiterates Buy Rating on GlaxoSmithKline (GSK:LN) (GSK)
-
Berenberg Reiterates Buy Rating on GlaxoSmithKline (GSK:LN) (GSK)
-
GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to GBP15.50 at JPMorgan
-
GSK (GSK): US FDA expands Jemperli plus chemotherapy approval
-
GSK (GSK) and Flagship Pioneering partner to discover novel medicines and vaccines
-
GlaxoSmithKline (GSK) PT Raised to $45 at Argus
-
ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
-
UBS Downgrades GlaxoSmithKline (GSK:LN) (GSK) to Neutral
-
Correct: FDA Evaluation Of Dolutegravir Risk Reported In 2018
-
GlaxoSmithKline (GSK:LN) (GSK) PT Lowered to GBP19 at Citi
-
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
-
GSK (GSK) 4K contracts of July 5 weekly 39 calls trade at 60c, 4K contracts trade at 35c
-
Midday movers: Micron, Levi Strauss, Walgreens and International Paper fall
-
Berenberg Reiterates Buy Rating on GlaxoSmithKline (GSK:LN) (GSK)
-
Zantac Not A Cause Of Woman’s Cancer, Jury Says In First Trial Over Drug - Reuters

